Advertisement
U.S. markets closed
Advertisement

MiNK Therapeutics, Inc. (INKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.0400-0.0100 (-0.95%)
At close: 04:00PM EST
1.0400 0.00 (0.00%)
After hours: 07:30PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close1.0500
Open1.0900
Bid1.0100 x 1300
Ask1.0500 x 1000
Day's Range1.0300 - 1.0900
52 Week Range0.8500 - 3.3400
Volume21,157
Avg. Volume40,682
Market Cap35.9M
Beta (5Y Monthly)-0.14
PE Ratio (TTM)N/A
EPS (TTM)-0.7300
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INKT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MiNK Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GuruFocus.com

    MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges

    Key Financial and Operational Highlights from MiNK Therapeutics' Third Quarter

  • GlobeNewswire

    MiNK Therapeutics Reports Third Quarter 2023 Results

    MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.Conference Call on Thursday, November 9, 2023, at 8:30 a.m. ET. NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a

  • GlobeNewswire

    MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

    Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioningAgenT-797 advancing in a randomized phase 2 trial in 2L gastric cancer NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allog